Compugen (CGEN) Q2 2026 earnings review
Cash Is Secured, Waiting on the Catalysts
For a clinical-stage biotech, financial results are less about operating leverage and entirely about runway and catalyst timelines. Compugen's Q2 2026 results reflect steady, planned execution. Revenue of $2.6M is simply the accounting recognition of previous Gilead milestones, while the $7.0M net loss aligns with expectations. The real story remains the fortress balance sheet ($125.3M in cash, funding operations into 2029) and the waiting game for partner data. With AstraZeneca expanding rilvegostomig into 12 Phase 3 trials and the fully-owned COM701 on track for Q1 2027 interim data, Compugen is well-capitalized to bridge the gap to its major inflection points.
🐂 Bull Case
AstraZeneca continues to aggressively expand rilvegostomig trials (now up to 12 Phase 3s) and reported strong 16.8-month overall survival data in biliary tract cancer at ASCO. This deeply de-risks Compugen's mid-single-digit royalty potential.
With $125.3M in cash and a runway stretching into 2029, Compugen has entirely eliminated the near-term dilution risk that typically plagues small-cap biotechs.
🐻 Bear Case
The interim median progression-free survival data for the wholly-owned COM701 program in the MAIA-ovarian trial won't arrive until Q1 2027, leaving the stock heavily dependent on external partner headlines.
Compugen lacks control over the timing, presentation, and strategic prioritization of its most valuable near-term assets (AZ's rilvegostomig and Gilead's GS-0321).
⚖️ Verdict: ⚪
Neutral. The company is executing perfectly on what it can control. The balance sheet is bulletproof through 2029, and AZ's data continues to validate the science. However, without major internal data until Q1 2027, the stock requires patience.
Key Themes
AstraZeneca's Expanding Rilvegostomig Ambitions
AstraZeneca is aggressively scaling its bet on rilvegostomig (PD-1/TIGIT bispecific derived from Compugen's COM902). The program expanded from 11 Phase 3 trials in Q1 to 12 Phase 3 trials in Q2. Furthermore, AZ presented first overall survival (OS) data from the GEMINI-Hepatobiliary study at ASCO 2026, showing a median OS of 16.8 months (vs historical 13 months). This external validation of the Fc-reduced TIGIT thesis is the primary near-term value driver.
COM701 MAIA-Ovarian Trial on Track
Compugen confirmed that its sponsored MAIA-ovarian adaptive platform trial evaluating COM701 as a maintenance monotherapy for platinum-sensitive ovarian cancer is progressing as planned. Management remains steadfast on delivering interim median progression-free survival (PFS) data by Q1 2027. Success here (targeting a 3+ month improvement over a ~5.5 month benchmark) would define the registration path.
Unigen AI Platform Continuity
The company continues to lean on its proprietary Unigen AI/ML computational discovery platform. Having successfully discovered the targets for COM701, COM902, and GS-0321, management emphasizes ongoing investment to generate the 'next wave' of novel immuno-oncology mechanisms, pivoting from hardware dependencies to deep, integrated software-driven biological discovery.
Long Wait for Internal Data
The timeline for the MAIA-ovarian readout (Q1 2027) forces investors into a prolonged holding pattern. While the cash runway into 2029 supports this timeline, the lack of significant, fully-owned clinical data in 2026 makes the stock highly vulnerable to broader biotech market sentiment and shifts in the TIGIT competitive landscape.
Partner-Controlled Narrative
With the Gilead (GS-0321) Phase 1 and AstraZeneca (rilvegostomig) Phase 3s dictating near-term momentum, Compugen is at the mercy of its partners' PR teams. The inability to guide on specific data disclosure timelines for these partnered assets creates a persistent information vacuum for investors.
Core Operating Burn Increasing
R&D expenses are Accelerating, growing from $5.6M in 25Q2 to $6.3M in 26Q2, largely driven by the MAIA-ovarian clinical trial scale-up. While completely covered by the massive cash pile, investors should monitor the burn rate as trial enrollment peaks to ensure the 2029 runway forecast holds without assuming future milestones.
Other KPIs
Accelerating. Up 12.5% YoY from $5.6 million in 25Q2. This increase is a direct result of the clinical ramp-up for the MAIA-ovarian trial and higher preclinical related expenses. As a percentage of total operating expenses, R&D stood at 73% for the first half of 2026, underscoring the company's commitment to advancing its pipeline.
Stable. Down sequentially from $134.9M in Q1 2026, reflecting the expected quarterly cash burn. Net cash used in operating activities for H1 2026 was $21.9 million, influenced by clinical costs and a $2.0M royalty payment to the Israel Innovation Authority. The balance sheet remains debt-free.
Decelerating. Down from $35.9 million at the end of 2025. This balance primarily represents the unamortized portions of Gilead's upfront and IND milestone payments, which are being recognized ratably over the Phase 1 trial period.
Guidance
Stable. Management reiterated that current cash balances will fund operating plans well into 2029 without the need for any additional cash inflows (like milestone payments). This provides exceptional visibility and downside protection.
Stable. The timeline for median progression-free survival data remains unchanged. Achieving a clear prolongation of PFS versus placebo here is the critical pivot point for Compugen's proprietary pipeline.
Key Questions
AstraZeneca Trial Expansion
AstraZeneca has expanded rilvegostomig into a 12th Phase 3 trial. Can you provide any color on the specific indication or combination strategy for this new trial, and how it impacts the $195M remaining milestone pool?
MAIA-Ovarian Enrollment Pace
With the Q1 2027 interim analysis target firmly established, are you currently seeing the 'aggressive enrollment rate' across the U.S., Israel, and France sites that was anticipated in previous quarters?
Unigen Pipeline Visibility
Given the extended gap until the COM701 data readout, is there a timeline for unveiling the next specific drug candidate generated by the Unigen platform to bridge the news flow?